Skip to main content
medRxiv
  • Home
  • About
  • Submit
  • ALERTS / RSS
Advanced Search

Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population

Alain Vanasse, Josiane Courteau, Yohann Chiu, André Cantin, Richard Leduc
doi: https://doi.org/10.1101/2020.04.08.20057893
Alain Vanasse
1Department of family medicine and emergency medicine, Université de Sherbrooke
2PRIMUS Research Group, Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • For correspondence: alain.vanasse@usherbrooke.ca
Josiane Courteau
2PRIMUS Research Group, Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Yohann Chiu
1Department of family medicine and emergency medicine, Université de Sherbrooke
2PRIMUS Research Group, Centre de recherche du Centre hospitalier universitaire de Sherbrooke (CRCHUS)
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
André Cantin
3Respiratory service, Medicine Department, Université de Sherbrooke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
Richard Leduc
4Department of pharmacology-physiology, Faculty of Medicine and Health Sciences, Institut de Pharmacologie, Université de Sherbrooke
  • Find this author on Google Scholar
  • Find this author on PubMed
  • Search for this author on this site
  • Abstract
  • Full Text
  • Info/History
  • Metrics
  • Data/Code
  • Preview PDF
Loading

ABSTRACT

Background Recent studies suggest that hydroxychloroquine (HCQ) could be effective against COVID-19. It is reasonable to expect that if HCQ can prevent or reduce the adverse effects of influenza, it may also reduce the effects of COVID-19 in humans. The objective of this study was to test whether HCQ can prevent or reduce the risk and severity of influenza.

Methods This is an observational cohort study using medico-administrative data from Québec. Patients included had at least one emergency department (ED) visit in 2012 or 2013, with a prior diagnosis of chronic conditions, and were admissible to the public drug insurance plan. Two sub-cohorts were considered depending on reasons for ED visit: other than influenza or pneumonia (primary prevention) and influenza or pneumonia (secondary prevention).

Results In the primary prevention analysis (n=417,353), patients taking HCQ (n=3,659) had an increased risk of hospitalization for pneumonia in the following year compared to those who did not (5.2% vs. 2.9%; adjusted OR=1.25, p=0.0079). In the secondary prevention analysis (n=27,152), patients taking HCQ (n=392), compared to those who did not had a modest and non-significant increased risk of hospitalization for pneumonia after 30 days (25.8% vs. 22.6%; adjusted OR=1.14, p=0.3177).

Interpretation Based on the assumption that HCQ has similar effects on the COVID-19 as those observed on influenza, we can infer that it will not have positive effects on COVID-19. We should therefore act cautiously before initiating prospective interventional studies on the use of HCQ to reduce adverse effects of COVID-19.

Competing Interest Statement

Prof. Vanasse has received federal and provincial funding for research in care trajectories and has no relevant personal financial or nonfinancial relationships to disclose. Dr. Cantin has received federal funding for research in idiopathic pulmonary fibrosis, funding for clinical research in pulmonary fibrosis from Boehringer-Ingelheim, and speaker fees related to cystic fibrosis from Vertex Pharmaceuticals Canada. Dr. Leduc received funding from the Canadian Institutes of Health Research related to SARS-CoV-2 research but has no relevant personal financial or nonfinancial relationships to disclose. The other authors report no competing interest.

Funding Statement

This project was made possible thanks to the availability of a medico-administrative database managed by the Alain Vanasse and Catherine Hudon team (co-investigators of a Fonds de recherche du Québec-Santé grant).

Author Declarations

All relevant ethical guidelines have been followed; any necessary IRB and/or ethics committee approvals have been obtained and details of the IRB/oversight body are included in the manuscript.

Yes

All necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived.

Yes

I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).

Yes

I have followed all appropriate research reporting guidelines and uploaded the relevant EQUATOR Network research reporting checklist(s) and other pertinent material as supplementary files, if applicable.

Yes

Data Availability

The datasets generated and/or analysed during the current study are not publicly available due to individual privacy but are available from the corresponding author on reasonable request.

Copyright 
The copyright holder for this preprint is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. It is made available under a CC-BY-NC-ND 4.0 International license.
Back to top
PreviousNext
Posted April 10, 2020.
Download PDF
Data/Code
Email

Thank you for your interest in spreading the word about medRxiv.

NOTE: Your email address is requested solely to identify you as the sender of this article.

Enter multiple addresses on separate lines or separate them with commas.
Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population
(Your Name) has forwarded a page to you from medRxiv
(Your Name) thought you would like to see this page from the medRxiv website.
CAPTCHA
This question is for testing whether or not you are a human visitor and to prevent automated spam submissions.
Share
Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population
Alain Vanasse, Josiane Courteau, Yohann Chiu, André Cantin, Richard Leduc
medRxiv 2020.04.08.20057893; doi: https://doi.org/10.1101/2020.04.08.20057893
Digg logo Reddit logo Twitter logo CiteULike logo Facebook logo Google logo Mendeley logo
Citation Tools
Hydroxychloroquine (HCQ): an observational cohort study in primary and secondary prevention of pneumonia in an at-risk population
Alain Vanasse, Josiane Courteau, Yohann Chiu, André Cantin, Richard Leduc
medRxiv 2020.04.08.20057893; doi: https://doi.org/10.1101/2020.04.08.20057893

Citation Manager Formats

  • BibTeX
  • Bookends
  • EasyBib
  • EndNote (tagged)
  • EndNote 8 (xml)
  • Medlars
  • Mendeley
  • Papers
  • RefWorks Tagged
  • Ref Manager
  • RIS
  • Zotero
  • Tweet Widget
  • Facebook Like
  • Google Plus One

Subject Area

  • Epidemiology
Subject Areas
All Articles
  • Addiction Medicine (70)
  • Allergy and Immunology (172)
  • Anesthesia (51)
  • Cardiovascular Medicine (456)
  • Dentistry and Oral Medicine (83)
  • Dermatology (55)
  • Emergency Medicine (160)
  • Endocrinology (including Diabetes Mellitus and Metabolic Disease) (192)
  • Epidemiology (5317)
  • Forensic Medicine (3)
  • Gastroenterology (199)
  • Genetic and Genomic Medicine (767)
  • Geriatric Medicine (81)
  • Health Economics (216)
  • Health Informatics (704)
  • Health Policy (364)
  • Health Systems and Quality Improvement (224)
  • Hematology (100)
  • HIV/AIDS (166)
  • Infectious Diseases (except HIV/AIDS) (5971)
  • Intensive Care and Critical Care Medicine (368)
  • Medical Education (107)
  • Medical Ethics (25)
  • Nephrology (83)
  • Neurology (781)
  • Nursing (43)
  • Nutrition (135)
  • Obstetrics and Gynecology (147)
  • Occupational and Environmental Health (237)
  • Oncology (483)
  • Ophthalmology (155)
  • Orthopedics (40)
  • Otolaryngology (98)
  • Pain Medicine (39)
  • Palliative Medicine (20)
  • Pathology (141)
  • Pediatrics (224)
  • Pharmacology and Therapeutics (138)
  • Primary Care Research (99)
  • Psychiatry and Clinical Psychology (868)
  • Public and Global Health (2051)
  • Radiology and Imaging (356)
  • Rehabilitation Medicine and Physical Therapy (160)
  • Respiratory Medicine (288)
  • Rheumatology (96)
  • Sexual and Reproductive Health (75)
  • Sports Medicine (77)
  • Surgery (110)
  • Toxicology (25)
  • Transplantation (30)
  • Urology (40)